@article{90036a3dfe534f1fa2864174290b3f1f,
title = "Lipid lowering in acute coronary syndrome is treatment early enough?",
author = "Nicholls, {Stephen J.} and Psaltis, {Peter J.}",
note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Nicholls reports that he is supported by a Principal Research Fellowship from the National Health and Medical Research Council of Australia. He also reports receiving research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, the Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and Liposcience and consultant fees from AstraZeneca, Amgen, Eli Lilly, Anthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, Kowa, CSL Behring, Esperion, and Boehringer Ingelheim. Dr Psaltis reports that he is supported by a Future Leader Fellowship from the National Heart Foundation of Australia. He also reports receiving research support from Abbott Vascular and honoraria from AstraZeneca, Merck, Pfizer, Esperion, and Bayer.",
year = "2018",
month = apr,
day = "3",
doi = "10.1001/jama.2018.2426",
language = "English",
volume = "319",
pages = "1325--1326",
journal = "JAMA : the journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "13",
}